Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922848 | 1.00 | NR1H2 (0.37) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| SCHEMBL1267010 | 1.00 | NR1H2 (0.37) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| SCHEMBL1266908 | 1.00 | NR1H2 (0.37) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL7191068 | 0.98 | NR1H2 (0.36) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL1137213 | 0.98 | NR1H2 (0.36) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| SCHEMBL28669712 | 0.85 | NR1H2 (0.35) | NR1H2KDM1ACHRM2CHRM1CHRM3 | |
| SCHEMBL28626040 | 0.84 | NR1H2 (0.39) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL77478 | 0.83 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL5203966 | 0.83 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3EPHX2 | |
| SCHEMBL142226 | 0.83 | CHRM2 (0.41) | NR1H2CHRM2CHRM1CHRM3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8039622-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-10-06 | — | — | US | disclosed |
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-09-29 | — | — | US | disclosed |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2011-09-15 | — | — | US | disclosed |
| EP-2350060-A2 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd (KR) | 2011-08-03 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7879852-B2 | such as (4S)-1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-yl]carbonyl}-4-[(4,4-dimethylcyclohexyl)(2,2-dimethylpropanoyl)amino]-N,N-dimethyl-L-prolineamide, used for the treatment of obesity, diabetes, inflammation and erectile dysfunction | LG LIFE SCIENCES LTD. (KR) | 2011-02-01 | — | — | US | disclosed |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCE LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099695-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | NR1H2 1166/4885KDM1A 2273/4885CHRM2 4884/4885 |
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | NR1H2 539/4885KDM1A 3496/4885CHRM2 396/4885 |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | NR1H2 539/4885KDM1A 3496/4885CHRM2 396/4885 |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | NR1H2 539/4885KDM1A 3496/4885CHRM2 396/4885 |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | NR1H2 539/4885KDM1A 3496/4885CHRM2 396/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | NR1H2 2872/4885KDM1A 1012/4885CHRM2 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.